肠道黏膜屏障在非酒精性脂肪性肝病发生发展中的作用

张媛媛; 李晶; 迟毓婧; 苏琳; 刘玉兰

doi:10.3969/j.issn.1001-5256.2016.12.035

肠道黏膜屏障在非酒精性脂肪性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2016.12.035

1. 北京大学人民医院消化内科
2. 北京大学人民医院中心实验室

基金项目:

国家自然科学基金青年项目(81200626,81200625,81500404)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2134
- HTML全文浏览量: 36
- PDF下载量: 447
- 被引次数: 0
出版历程
- 出版日期: 2016-12-20

Role of intestinal mucosal barrier in the development and progression of nonalcoholic fatty liver disease

Research funding:

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)在我国的发病率逐年上升。肠道黏膜是人体内最大的细菌储存器官,肠道黏膜屏障包括生物屏障、机械屏障、免疫屏障和化学屏障。探讨了肠道黏膜屏障功能在NAFLD发病机制中的重要作用。肠道生物屏障方面,肠道菌群的异常早于肥胖等代谢异常的发生;小肠细菌过度生长可以影响能量代谢、促进胰岛素抵抗等,可能参与了NAFLD的发病过程;调节肠道菌群对于治疗NAFLD具有一定疗效。肠道机械屏障功能受损,黏膜通透性增加,与肠道菌群失调有关;肠道免疫屏障的变化可能与肥胖、代谢紊乱以及肝脏炎症状态相关;肠道化学屏障的改变可抑制肝细胞极低密度脂蛋白及低密度脂蛋白的合成和分泌,可能会导致肝脏TG沉积。指出了肠道黏膜屏障功能的研究为NAFLD的预防和治疗提供了广阔的前景。
- 脂肪肝 /
- 肠杆菌科 /
- 综述
Abstract: The incidence of non- alcoholic fatty liver disease( NAFLD) has been increasing year by year in China. Intestinal mucosa is the largest organ for bacterial storage,and intestinal mucosal barrier includes biological barrier,mechanical barrier,immunological barrier,and chemical barrier. This article investigates the important role of intestinal mucosal barrier function in the pathogenesis of NAFLD. As for the intestinal biological barrier,abnormalities in gut microbiota occur earlier than obesity and other metabolic disorders; small intestinal bacterial overgrowth may affect energy metabolism,promote insulin resistance,and get involved in the pathogenesis of NAFLD; regulation of gut microbiota has a certain clinical effect in the treatment of NAFLD. Intestinal mechanical barrier impairment increases the mucosal permeability and is associated with intestinal dysbacteriosis. The changes in intestinal immunological barrier may be associated with obesity,metabolic disorders,and liver inflammation. The changes in intestinal chemical barrier can inhibit the synthesis and secretion of very low- density lipoprotein and low- density lipoprotein in hepatocytes and may result in triglyceride deposition in the liver. It is pointed out that the research on intestinal mucosal barrier function provides promising prospects for the prevention and treatment of NAFLD.
- fatty liver /
- interobacteriaceae /
- review

HTML全文

参考文献(31)

[1]WANG FG,LIANG WF,XI JJ,et al.Establishment and applications of non-alcoholic steatohepatitis animal models[J].Chin J Clin Pharmacol Ther,2015,20(7):835-840.(in Chinese)王福根,梁伟峰,席建军,等.非酒精性脂肪性肝炎动物模型的建立与应用[J].中国临床药理学与治疗学,2015,20(7):835-840.

[2]LONARDO A,BALLESTRI S,MARCHESINI G,et al.Nonalcoholic fatty liver disease:a precursor of the metabolic syndrome[J].Dig Liver Dis,2015,47(3):181-190.

[3]DAY CP.Non-alcoholic steatohepatitis(NASH):where are we now and where are we going?[J].Gut,2002,50(5):85-88.

[4]VEENA J,MURAGUNDLA A,SIDGIDDI S,et al.Non-alcoholic fatty liver disease:need for a balanced nutritional source[J].Br J Nutr,2014,112(11):1858-1872.

[5]KAMADA N,SEO SU,CHEN GY,et al.Role of the gut microbiota in immunity and inflammatory disease[J].Nat Rev Immunol,2013,13(5):321-335.

[6]LIN HV,FRASSETTO A,KOWALIK EJ Jr,et al.Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms[J].PLo S One,2012,7(4):e35240.

[7]KALLIOMAKI M,COLLADO MC,SALMINEN S,et al.Early differences in fecal microbiota composition in children may predict overweight[J].Am J Clin Nutr,2008,87(3):534-538.

[8]BACKHED F,MANCHESTER JK,SEMENKOVICH CF,et al.Mechanisms underlying the resistance to diet-induced obesity in germ-free mice[J].Proc Natl Acad Sci U S A,2007,104(3):979-984.

[9]MA RJ,WU J,ZHOU YN,et al.Relationship between intestinal microflora imblance and nonalcoholic fatty liver disease[J].J Clin Hepatol,2015,31(1):127-129.(in Chinese)麻瑞娟,吴静,周永宁.肠道微生态失衡与非酒精性脂肪性肝病的关系[J].临床肝胆病杂志,2015,31(1):127-129.

[10]VIGGIANO D,IANIRO G,VANELLA G,et al.Gut barrier in health and disease:focus on childhood[J].Eur Rev Med Pharmacol Sci,2015,19(6):1077-1085.

[11]FEROLLA SM,ARMILIATO GN,COUTO CA,et al.Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease[J].World J Hepatol,2015,7(3):559-565.

[12]FUKUI H.Gut-liver axis in liver cirrhosis:how to manage leaky gut and endotoxemia[J].World J Hepatol,2015,7(3):425-442.

[13]ESPOSITO E,IACONO A,BIANCO G,et al.Probiotics reduce the inflammatory response indeced by a high-fat diet in the liver of young rats[J].J Nutr,2009,139(5):905-911.

[14]MENCARELLI A,CIPRIANI S,RENGA B,et al.VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation[J].PLo S One,2012,7(9):e45425.

[15]CHASSAING B,ETIENNE-MESMIN L,GEWIRTZ AT.Microbiota-liver axis in hepatic disease[J].Hepatology,2014,59(1):328-339.

[16]ROH YS,SEKI E.Toll-like receptors in alcoholic liver disease,non-alcoholic steatohepatitis and carcinogenesis[J].J Gastroenterol Hepatol,2013,28(Suppl 1):38-42.

[17]WOOD NJ.Dysbiosis driven by inflammasome deficiency exacerbates hepatic steatosis and governs rate of NAFLD progression[J].Nat Rev Gastroenterol Hepatol,2012,9(3):123.

[18]HENAO-MEJIA J,ELINAV E,JIN C,et al.Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J].Nature,2012,482(7384):179-185.

[19]FIALHO A,FIALHO A,THOTA P,et al.Small intestinal bacterial overgrowth is associated with nonalcoholic fatty liver disease[J].J Gastrointestin Liver Dis,2016,25(2):159-165.

[20]SHANAB AA,SCULLY P,CROSBIE O,et al.Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis:association with Toll-like receptor 4 expression and plasma levels of interleukin 8[J].Dig Dis Sci,2011,56(5):1524-3154.

[21]FEROLLA SM,ARMILIATO GN,COUTO CA,et al.The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease[J].Nutrients,2014,6(12):5583-5599.

[22]FUKUNISHI S,SUJISHI T,TAKESHITA A,et al.Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats[J].J Clin Biochem Nutr,2014,54:39-44.

[23]WELLS JM,ROSSI O,MEIJERINK M,et al.Epithelial cross-talk at the microbiota-mucosal interface[J].Proc Natl Acad Sci U S A,2011,108(Suppl 1):4607-4614.

[24] SHEN L,SU L,TURNER JR.Mechanisms and functional implications of intestinal barrier defects[J].Dig Dis,2009,27(4):443-449.

[25]MIELE L,VALENZA V,LA TORRE G,et al.Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease[J].Hepatology,2009,49(6):1877-1887.

[26] ZHANG YY,LI J,CHI YJ,et al.Myosin light chain kinase involved in change of intestinal mucosal barrier function in nonalcoholic steatohepatitis mice model[J].Chin J Intern Med,2015,54(5):434-438.(in Chinese)张媛媛,李晶,迟毓静,等.肌球蛋白轻链激酶MLCK在非酒精性脂肪性肝炎小鼠模型肠粘膜屏障变化中的作用研究[J].中华内科杂志,2015,54(5):434-438.

[27]BIEGHS V,TRAUTWEIN C.Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease[J].Hepatobiliary Surg Nutr,2014,3(6):377-385.

[28]KIM CS,LEE SC,KIM YM,et al.Visceral fat accumulation induced by a high-fat diet causes the atrophy of mesenteric lymph nodes in obese mice[J].Obesity,2008,16(6):1261-1269.

[29]LU X,HAN T,TIAN Y,et al.Research progress in roles of gut microbiota and bile acid metabolism in development and progression of NAFLD[J].J Clin Hepatol,2014,30(11):1225-1228.(in Chinese)鲁旭,韩涛,田壵,等.肠道菌群面胆汁酸代谢对非酒精性脂肪性肝病发生发展的作用[J].临床肝胆病杂志,2014,30(11):1225-1228.

[30]MARTIN FP,DUMAS ME,WANG Y,et al.A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model[J].Mol Syst Biol,2007,3:112.

[31]MINEMURA M,SHIMIZU Y.Gut microbiota and liver diseases[J].World J Gastroenterol,2015,21(6):1691-1702.

施引文献

资源附件(0)

访问统计